Clinical trial
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or…
NCT00061126 · Abgenix, Industry · Completed
Key facts
| NCT number | NCT00061126 |
|---|---|
| Title | ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body |
| Official title | A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis |
| Lead sponsor | Abgenix, Industry |
| Collaborators | Immunex Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ABX-EGF |
| Enrollment | 50 |
| Start date | Apr 1, 2003 |
| First posted | May 22, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: